The Program Administration Core will facilitate the overall goals of the Program by providing administrative and fiscal support as well as scientific oversight, to ensure that the activities of the Program are consistent with its ultimate goal i.e. the development of new targeted therapies for non-small cell lung cancer. This involves coordination of all Programmatic activities, in particular promoting collaboration, cross-talk and sharing of information and ideas between the various Projects and Cores. This includes the assessment and implementation of changes in research trajectory, as required, to ensure research progress and alignment of activities with the overall goals of the program. This will be accomplished via the following Specific Aims:
Specific Aim 1 : Monitor projects and shared resource cores and evaluate overall research progress. a) Coordinate regular meetings of a Program Executive Committee, including each of the Project Leaders and Core Directors, to monitor the progress of each Project and Shared Resource Core. b) Provide regular guidance to the Project Leaders and Core Directors, including critical evaluation of research progress and direction. c) Obtain advice from an Internal Advisory Committee of scientists within Dana-Farber Cancer Institute, and monitor the integration of the committee?s suggestions into the performance of the Projects and Cores. d) Hold meetings of an External Advisory Board of scientists with expertise in lung cancer targeted therapies.
Specific Aim 2 : Foster collaboration and communication among the projects and shared resource cores. a) Arrange bi-weekly group meetings of the Program to share research ideas, results, and methods. b) Monitor and encourage the interactions between projects and cores.
Specific Aim 3 : Provide fiscal oversight and support for the program. a) Assist with grants management and disbursement of funds. b) Analyze and adjust budgets to incorporate ongoing innovations and as the program evolves.
Specific Aim 4 : Promote the clinical translation of diagnostic and therapeutic discoveries from the program. a) Ensure that translatable discoveries are effectively communicated to the Dana-Farber/Harvard Cancer Center Lung Cancer Program. b) Organize a retreat to disseminate the research findings and prompt synergistic interactions. c) Assist in manuscript submission and subsequent publication.

Public Health Relevance

The purpose of the Program Administration Core is to provide scientific, financial and administrative stewardship of the overall Program in ?Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma?. The Core will serve as a central node for the coordination of all joint Programmatic activities and will promote the internal collaboration and synergy between the Projects and Cores required to achieve the goal of the program: to develop new and durable targeted therapies to treat lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA154303-07
Application #
9553654
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
7
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
Gannon, Hugh S; Zou, Tao; Kiessling, Michael K et al. (2018) Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun 9:5450
Aguirre, Andrew J; Hahn, William C (2018) Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harb Perspect Med 8:
Rowbotham, S P; Li, F; Dost, A F M et al. (2018) H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Nat Commun 9:4559
Deng, Jiehui; Wang, Eric S; Jenkins, Russell W et al. (2018) CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8:216-233
Terai, Hideki; Kitajima, Shunsuke; Potter, Danielle S et al. (2018) ER Stress Signaling Promotes the Survival of Cancer ""Persister Cells"" Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res 78:1044-1057
Rusan, Maria; Li, Kapsok; Li, Yvonne et al. (2018) Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discov 8:59-73
Adeegbe, Dennis O; Liu, Shengwu; Hattersley, Maureen M et al. (2018) BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res 6:1234-1245
Tan, Li; Gurbani, Deepak; Weisberg, Ellen L et al. (2017) Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem 25:838-846
Tan, Li; Gurbani, Deepak; Weisberg, Ellen L et al. (2017) Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorg Med Chem 25:1320-1328
Adeegbe, Dennis O; Liu, Yan; Lizotte, Patrick H et al. (2017) Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer Discov 7:852-867

Showing the most recent 10 out of 80 publications